Biomarkers of sick sinus syndrome
病态窦房结综合征的生物标志物
基本信息
- 批准号:8869030
- 负责人:
- 金额:$ 25.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-07 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:AgeArrhythmiaBiochemical MarkersBiological AssayBiological MarkersBiological ModelsBioprobeBiosensing TechniquesBiosensorBloodBlood CirculationBlood TestsBlood specimenCardiacCaringClinicClinicalComplexCoupledDevelopmentDevicesDiagnosisDiagnosticDiagnostic SensitivityEarly DiagnosisElectrocardiogramEnvironmentEnzyme-Linked Immunosorbent AssayFunctional disorderGoldHealth Care CostsHealthcareHeart DiseasesHigh Pressure Liquid ChromatographyHolter ElectrocardiographyHospitalsHourImageImmunoassayLeadLogisticsMagnetic nanoparticlesMediatingMedicalMyoglobinOpticsOutcomePathogenesisPatient CarePatientsPlasmaPolymerase Chain ReactionPredictive ValuePredispositionProceduresProteinsReportingResourcesRouteSamplingSemiconductorsSensitivity and SpecificitySick Sinus SyndromeSinusSocietiesSolidSpecificitySpottingsSudden DeathSurface Plasmon ResonanceSurvival RateSystemSystems IntegrationTechniquesTest ResultTestingTimeTissuesTranslational ResearchTriageTroponin IUnited Statesbasebiochipclinical practicedesigndetectorimprovedinnovationinsightinstrumentinterdisciplinary approachinterestmetal oxidemicro-total analysis systemnanonanobiosensornanobiotechnologynanoparticlenanorodpoint of carerapid diagnosissensorsudden cardiac deathtechnology development
项目摘要
DESCRIPTION (provided by applicant): In the ageing society, sick sinus syndrome (SSS) is rapidly becoming one of the major arrhythmia problems. High survival rate with appropriate medical care indicates the paramount importance of early diagnosis. Interests have intensified in plasma biochemical markers to predict susceptibility and aid in patient management. Cardiac troponin I (cTnI) is the most widely used biomarker, due to its nearly complete cardiac tissue specificity. An elevated cTnI concentration was reported to be associated with SSS. A combination of cTnI and myoglobin, one of the earliest biomarkers released into blood circulation, can achieve diagnostic sensitivity of 97% with a 99% negative predictive value within 90 mins of ED presentation. However, blood testing of these biomarkers in current clinical practice represents a challenge for prime time diagnosis due to the time delay caused by laborious analysis and the logistics of sample handling to central labs. Therefore, the objective of this project is to take a multidisciplinary approach to develop an innovative biochip for rapid and simultaneous biosensing of these proteins at point of patient care. Specifically, a nanoparticle surface plasmon resonance (nanoSPR) biochip based on gold nanorod probes will be developed. Effect of the magnetic nanoparticles on the nanoSPR sensitivity and specificity enhancement will be systematically studied. The nano-biochip will then be integrated with a highly sensitive CMOS (complementary metal oxide semiconductor) image sensor and nanohole array to develop an innovative, fully operational lab-on-a-chip biosensor. The fundamental studies will provide innovative insights into MNP mediated nanoSPR mechanism to develop an ultra-sensitive, multiplexed biosensing. System integration of nanoSPR biochip with portable optical detector will transform bio-analysis in clinical environment to a point of care format for prime time medical diagnostics to improve clinical outcome.
描述(由申请人提供):在老龄化社会中,病窦综合征(SSS)正迅速成为主要的心律失常问题之一。在适当的医疗护理下,高存活率表明早期诊断至关重要。人们对血浆生化标志物预测易感性和帮助患者管理的兴趣越来越大。心肌肌钙蛋白I(cTnI)是最广泛使用的生物标志物,由于其几乎完全的心脏组织特异性。据报告,cTnI浓度升高与SSS相关。cTnI和肌红蛋白(最早释放到血液循环中的生物标志物之一)的组合可以在艾德出现的90分钟内实现97%的诊断灵敏度和99%的阴性预测值。然而,在目前的临床实践中,这些生物标志物的血液检测代表了对黄金时间诊断的挑战,这是由于费力的分析和将样本处理到中心实验室的物流造成的时间延迟。因此,该项目的目标是采取多学科方法开发一种创新的生物芯片,用于在患者护理点快速同时生物传感这些蛋白质。具体而言,纳米粒子表面等离子体共振(nanoSPR)生物芯片的基础上,金纳米棒探针将被开发。磁性纳米粒子对纳米SPR灵敏度和特异性增强的影响将被系统地研究。然后,纳米生物芯片将与高灵敏度的CMOS(互补金属氧化物半导体)图像传感器和纳米孔阵列集成,以开发创新的、完全可操作的芯片实验室生物传感器。基础研究将为MNP介导的nanoSPR机制提供创新见解,以开发超灵敏,多路复用的生物传感。nanoSPR生物芯片与便携式光学检测器的系统集成将临床环境中的生物分析转变为用于黄金时间医学诊断的护理点格式,以改善临床结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Liang Tang其他文献
Liang Tang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Liang Tang', 18)}}的其他基金
STRUCTURAL STUDIES OF BACTERIAL PROTEIN COMPLEXES
细菌蛋白复合物的结构研究
- 批准号:
8362145 - 财政年份:2011
- 资助金额:
$ 25.29万 - 项目类别:
STRUCTURAL STUDIES OF BACTERIAL PROTEIN COMPLEXES
细菌蛋白复合物的结构研究
- 批准号:
8170085 - 财政年份:2010
- 资助金额:
$ 25.29万 - 项目类别:
相似海外基金
DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
- 批准号:
495592 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
- 批准号:
23K14885 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains
闰盘细胞外纳米结构域调节心律失常的机制
- 批准号:
10668025 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
Development of a next-generation telemonitoring system for prognostic prediction of the onset of heart failure and arrhythmia
开发下一代远程监测系统,用于心力衰竭和心律失常发作的预后预测
- 批准号:
23K09597 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of inflammation in the pathogenesis of atrial fibrillation: Implications for atrial remodeling pathophysiology and for early atrial arrhythmia recurrences following radiofrequency ablation and pulsed field ablation
炎症在心房颤动发病机制中的作用:对心房重塑病理生理学以及射频消融和脉冲场消融后早期房性心律失常复发的影响
- 批准号:
514892030 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
WBP Fellowship
Improved arrhythmia ablation via MR-guided robotic catheterization and multimodal clinician feedback
通过 MR 引导的机器人导管插入术和多模式临床医生反馈改善心律失常消融
- 批准号:
10638497 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
- 批准号:
10722857 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility
Ca2 稳态和心律失常易感性的新型调节剂
- 批准号:
10724935 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
Novel Stellate Ganglia Chemo-ablation Approach to Treat Cardiac Arrhythmia and Cardiac Remodeling in Heart Failure
新型星状神经节化疗消融方法治疗心律失常和心力衰竭心脏重塑
- 批准号:
10727929 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 25.29万 - 项目类别:














{{item.name}}会员




